Clinical efficacy of inhaled corticosteroids in patients with coronavirus disease 2019: A living review and meta-analysis
Su-Yeon Yu, Miyoung Choi, Seungeun Ryoo, Chelim Cheong, Kyungmin Huh, Young Kyung Yoon, Su Jin Jeong
PLOS ONE, doi:10.1371/journal.pone.0294872
Inhaled corticosteroids are known to be relatively safe for long-term use in inflammatory respiratory diseases and it has been repurposed as one of the potential therapies for outpatients with coronavirus disease 2019 (COVID-19). However, inhaled corticosteroids have not been accepted for COVID-19 as a standard therapy because of its lack of proven benefits. Therefore, this study aimed to evaluate the effectiveness of inhaled corticosteroids in patients with COVID-19. Randomized controlled trials comparing the efficacy of inhaled corticosteroid treatment in patients with COVID-19 were identified through literature electronic database searches up to March 10, 2023. Meta-analyses were conducted for predefined outcomes, and the certainty of evidence was graded using the grading of recommendations, assessment, development, and evaluation approach. Overall, seven trials (eight articles) were included in this systematic review. Compared with usual care, inhaled corticosteroids was associated with significantly improved clinical recovery at 7 and 14 days in patients with COVID-19. In subgroup analysis, only budesonide showed significant efficacy in clinical recovery, whereas no significant benefit was observed for ciclesonide. Moreover, inhaled corticosteroids use was not significantly associated with all-cause hospitalization, all-cause mortality, admission to intensive care unit, or the use of mechanical ventilation. Our systematic review used evidence with very low to moderate certainty. Although based on limited evidence, our results suggest that inhaled corticosteroids treatment, especially budesonide, improves the clinical recovery of patients with COVID-19. More trials and meta-analyses are needed to assess the efficacy of inhaled corticosteroids for COVID-19 treatment.
References
Brodin, Tornhammar, Ueda, Krifors, Westerlund et al., Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19), BMJ open,
doi:10.1136/bmjopen-2022-064374Clemency, Varughese, Gonzalez-Rojas, Morse, Phipatanakul et al., Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial, JAMA internal medicine,
doi:10.1001/jamainternmed.2021.6759Cumpston, Li, Page, Chandler, Welch et al., Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions, Cochrane Database Syst Rev,
doi:10.1002/14651858.ED000142Doi, Tomita, Okura, Matsuyama, Frequent occurrence of mutations in nsp3 and nsp4 of SARS-CoV-2, presumably caused by the inhaled asthma drug ciclesonide, PNAS Nexus,
doi:10.1093/pnasnexus/pgac197Donahue, Weiss, Livingston, Goetsch, Greineder et al., Inhaled steroids and the risk of hospitalization for asthma, JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Duvignaud, Lhomme, Onaisi, Sitta, Gelley et al., Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COV-ERAGE), Clinical Microbiology and Infection,
doi:10.1016/j.cmi.2022.02.031Ezer, Belga, Daneman, Smith, Daniels, Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial, BMJ (Clinical Research,
doi:10.1136/bmj-2021-068060Griesel, Wagner, Mikolajewska, Stegemann, Fichtner et al., Inhaled corticosteroids for the treatment of COVID-19, Cochrane Database of Systematic Reviews (Online
Guyatt, Thorlund, Oxman, Walter, Patrick et al., GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes, J Clin Epidemiol,
doi:10.1016/j.jclinepi.2012.08.001Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in Hospitalized Patients with Covid-19, New England Journal of Medicine,
doi:10.1056/NEJMoa2021436Irwin, Baumann, Bolser, Boulet, Braman et al., Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines, Chest,
doi:10.1378/chest.129.1_suppl.1SJeon, Ko, Lee, Choi, Byun et al., Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs, Antimicrobial Agents and Chemotherapy,
doi:10.1128/AAC.00819-20Kelly, Comparison of inhaled corticosteroids: an update, ANNALS OF PHARMACOTHERAPY,
doi:10.1345/aph.1L546Kew, Seniukovich, Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease, Cochrane Database of Systematic Reviews (Online,
doi:10.1002/14651858.CD010115.pub2Latorre, Novelli, Vagaggini, Braido, Papi et al., Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): role of ICS, Pulmonary Pharmacology & Therapeutics,
doi:10.1016/j.pupt.2014.10.006Liberati, Altman, Tetzlaff, Mulrow, Gøtzsche et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, Journal of clinical epidemiology,
doi:10.1016/j.jclinepi.2009.06.006Masjedi, Esmaeil, Saffaei, Naeini, Pourazizi et al., Cytokine Indexes in Pemphigus Vulgaris: Perception of Its Immunpathogenesis and Hopes for Non-Steroidal Treatment, Iranian journal of pharmaceutical research
Matsuyama, Kawase, Nao, Shirato, Ujike et al., The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells, Journal of Virology,
doi:10.1128/JVI.01648-20Mattos-Silva, Felix, Silva, Robba, Battaglini et al., Pros and cons of corticosteroid therapy for COVID-19 patients, Respiratory Physiology & Neurobiology,
doi:10.1016/j.resp.2020.103492Meduri, Muthiah, Carratu, Eltorky, Chrousos, Nuclear factor-kappaB-and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids, Neuroimmunomodulation,
doi:10.1159/000091126Milne, Li, Yang, Filho, ´ndez Cordero et al., Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial, Eur Respir J,
doi:10.1183/13993003.00130-2021Moghadasi, Shabany, Heidari, Eskandarieh, Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?, Clinical Neurology and Neurosurgery,
doi:10.1016/j.clineuro.2021.106563Mutch, Nave, Mccracken, Zech, Williams, The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue, Biochemical Pharmacology,
doi:10.1016/j.bcp.2007.01.031Nieto, Mazon, Pamies, Linana, Lanuza et al., Adverse effects of inhaled corticosteroids in funded and nonfunded studies, Archives of Internal Medicine,
doi:10.1001/archinte.167.19.2047Peters, Sajuthi, Deford, Christenson, Rios et al., COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids, Am J Respir Crit Care Med,
doi:10.1164/rccm.202003-0821OCRamakrishnan, Nicolau, Jr, Langford, Mahdi et al., Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial, The Lancet Respiratory Medicine,
doi:10.1016/S2213-2600(21)00160-0Singanayagam, Glanville, Girkin, Ching, Marcellini et al., Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations, Nature Communications
Song, Yoon, Seo, Lee, Eom et al., Ciclesonide inhaler treatment for mild-tomoderate COVID-19: a randomized, open-label, phase 2 trial, Journal of Clinical Medicine,
doi:10.3390/jcm10163545Southworth, Pattwell, Khan, Mowbray, Strieter et al., Increased type 2 inflammation post rhinovirus infection in patients with moderate asthma, Cytokine,
doi:10.1016/j.cyto.2019.154857Sterne, Murthy, Diaz, Slutsky, Villar et al., Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis, JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,
doi:10.1001/jama.2020.17023Terada-Hirashima, Suzuki, Tsujimoto, Hamamoto, Uemura et al., Impact of inhaled ciclesonide on asymptomatic or mild COVID-19: A randomized trial, Drug Discov Ther,
doi:10.5582/ddt.2022.01068Van Rensen, Straathof, Veselic-Charvat, Zwinderman, Bel et al., Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma, Thorax,
doi:10.1136/thx.54.5.403Yang, Du, Chen, Jiang, Xu, Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials, International Immunopharmacology,
doi:10.1016/j.intimp.2019.105950Yang, Zhang, Chen, Lin, Zeng et al., Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis, Infection,
doi:10.1007/s15010-018-1229-yYu, Bafadhel, Dorward, Hayward, Saville et al., Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet,
doi:10.1016/S0140-6736(21)01744-XZhu, Zhang, Li, Yang, Song, A Novel Coronavirus from Patients with Pneumonia in China, 2019, New England Journal of Medicine,
doi:10.1056/NEJMoa2001017
